Core Viewpoint - Wall Street anticipates flat earnings for SKYX Platforms Corp. with a projected quarterly loss of $0.08 per share and revenues of $23.2 million, reflecting a 4.7% increase year-over-year [1][3]. Earnings Expectations - The consensus EPS estimate has been revised down by 33.33% over the last 30 days, indicating a reassessment by analysts [4]. - A positive or negative Earnings ESP reading can indicate the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. Earnings Surprise Prediction - The Most Accurate Estimate for SKYX is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, making it challenging to predict an earnings beat [12]. - SKYX currently holds a Zacks Rank of 3, which does not strongly indicate an earnings beat [12]. Historical Performance - In the last reported quarter, SKYX matched the expected loss of $0.08 per share, resulting in no surprise [13]. - Over the past four quarters, SKYX has beaten consensus EPS estimates twice [14]. Industry Comparison - Bitdeer Technologies Group (BTDR) is expected to report a loss of $0.22 per share, a year-over-year change of +37.1%, with revenues projected at $161.14 million, up 159.8% from the previous year [18][19]. - The consensus EPS estimate for Bitdeer has been revised 40% higher in the last 30 days, with a positive Earnings ESP of +27.27%, suggesting a likely earnings beat [19][20].

Core Viewpoint - Somnigroup International (SGI) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on November 6, with a consensus EPS estimate of $0.85 per share, reflecting a year-over-year increase of +3.7% [3]. - Revenues are projected to reach $2.07 billion, representing a substantial increase of 59% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 4.17% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for SGI is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.53%, suggesting a bullish outlook on the company's earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - SGI currently holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - SGI has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters [14]. - In the last reported quarter, SGI was expected to post earnings of $0.51 per share but delivered $0.53, resulting in a surprise of +3.92% [13]. Conclusion - While SGI is positioned as a compelling earnings-beat candidate, it is essential to consider other factors that may influence stock performance beyond earnings results [15][17].

Core Insights - Arcellx, Inc. (ACLX) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended September 2025, with a consensus EPS estimate of a loss of $0.96 per share, reflecting a -100% change [1][3] - Revenues are projected to be $14.64 million, down 43.8% from the same quarter last year [3] - The consensus EPS estimate has been revised 12.39% higher in the last 30 days, indicating a reassessment by analysts [4] Earnings Expectations - The upcoming earnings report could lead to a stock price increase if results exceed expectations, while a miss could result in a decline [2] - The Earnings Whisper model suggests that revisions prior to earnings releases provide insights into business conditions [7] Earnings Surprise Prediction - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with a positive Earnings ESP indicating a likely earnings beat [8][9] - For Arcellx, the Most Accurate Estimate is higher than the consensus, resulting in an Earnings ESP of +7.60%, suggesting a strong likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Arcellx was expected to post a loss of $1.03 per share but actually reported a loss of -$0.94, achieving a surprise of +8.74% [13] - Over the past four quarters, Arcellx has beaten consensus EPS estimates two times [14] Industry Context - Another company in the biomedical sector, Geron (GERN), is expected to report a loss of $0.03 per share, indicating a year-over-year change of +25%, with revenues projected at $52.49 million, up 85.7% [18] - Geron's consensus EPS estimate has been revised 7.7% lower, resulting in an Earnings ESP of -32.35%, combined with a Zacks Rank of 4 (Sell), making it challenging to predict an earnings beat [19][20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for MP Materials Corp. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Company Summary - The upcoming earnings report for MP Materials is expected to show a quarterly loss of $0.14 per share, reflecting a year-over-year change of -16.7% [3]. - Revenues are projected to be $53.14 million, down 15.6% from the same quarter last year [3]. - The consensus EPS estimate has been revised 13.04% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for MP Materials is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.77%, suggesting a likelihood of beating the consensus EPS estimate [12]. Earnings Surprise History - In the last reported quarter, MP Materials was expected to post a loss of $0.17 per share but actually reported a loss of -$0.13, resulting in a positive surprise of +23.53% [13]. - Over the last four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the Zacks Mining - Miscellaneous industry, Ur Energy is expected to post a loss of $0.03 per share, indicating a year-over-year change of -50% [18]. - Ur Energy's revenue is expected to be $6.83 million, up 6.7% from the previous year [18]. - The consensus EPS estimate for Ur Energy has been revised 33.3% lower in the last 30 days, resulting in an Earnings ESP of -12.50%, making it difficult to predict a beat on the consensus EPS estimate [19].

Core Insights - Eos Energy Enterprises, Inc. (EOSE) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus estimate of a loss of $0.29 per share, reflecting a 34.1% improvement from the previous year [1][3] - Revenues are projected to reach $39.81 million, representing a significant increase of 4583.5% compared to the same quarter last year [3] - The earnings report is anticipated to be released on November 5, and the actual results will be crucial in determining the stock's near-term price movement [2] Estimate Revisions Trend - The consensus EPS estimate has been revised 6.86% higher in the last 30 days, indicating a collective reassessment by analysts [4] - Despite the upward revision, the Most Accurate Estimate for Eos Energy is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -53.85%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Eos Energy was expected to post a loss of $0.17 per share but instead reported a loss of $1.05, resulting in a surprise of -517.65% [13] - The company has not been able to beat consensus EPS estimates in any of the last four quarters, indicating a consistent trend of underperformance [14] Bottom Line - Eos Energy does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding this stock ahead of its earnings release [17]

Core Insights - Wall Street anticipates a year-over-year decline in earnings for NewAmsterdam Pharma Company N.V. (NAMS) due to lower revenues, with a consensus expectation of a quarterly loss of $0.38 per share, reflecting a -111.1% change from the previous year [1][3] - Revenues are projected to be $3.88 million, which is an 86.7% decrease compared to the same quarter last year [3] - The stock's price movement will largely depend on how actual results compare to these estimates, with a potential for upward movement if results exceed expectations [2] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.95% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for NewAmsterdam Pharma is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +19.13%, suggesting a likelihood of beating the consensus EPS estimate [12] Earnings Surprise History - In the last reported quarter, NewAmsterdam Pharma was expected to post a loss of $0.52 per share but actually reported a loss of -$0.15, resulting in a positive surprise of +71.15% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Drugs industry, Corcept Therapeutics is expected to report earnings of $0.18 per share, indicating a year-over-year decline of -56.1%, with revenues expected to be $219.18 million, up 20.1% from the previous year [19] - Corcept's consensus EPS estimate has been revised down by 9.7% over the last 30 days, and it has a negative Earnings ESP of -72.60%, combined with a Zacks Rank of 5 (Strong Sell), making it challenging to predict an earnings beat [20]

Core Insights - Praxis Precision Medicines, Inc. (PRAX) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025 [1][3] - The consensus EPS estimate for the upcoming report is a loss of $3.45 per share, reflecting a 25.5% decrease year-over-year, while revenues are expected to be $0.33 million, up 10% from the previous year [3] Earnings Expectations - The earnings report could lead to a stock price increase if the actual results exceed expectations; conversely, missing estimates may result in a stock price decline [2] - The consensus EPS estimate has been revised down by 0.5% over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Praxis Precision Medicines is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.35%, suggesting a bullish outlook from analysts [12] - The stock currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Praxis Precision Medicines was expected to post a loss of $3.4 per share but actually reported a loss of -$3.31, achieving a surprise of +2.65% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - PTC Therapeutics (PTCT), another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.19 per share for the same quarter, which represents a year-over-year increase of 14.4% [18] - PTC Therapeutics has an Earnings ESP of +5.75% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Perrigo despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Perrigo is expected to report quarterly earnings of $0.75 per share, reflecting a year-over-year decrease of 7.4%, while revenues are projected to be $1.1 billion, an increase of 0.8% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.92% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Perrigo is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.33%, suggesting bearish sentiment among analysts [12]. Historical Performance - In the last reported quarter, Perrigo was expected to earn $0.59 per share but only achieved $0.57, resulting in a surprise of -3.39%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13][14]. Investment Considerations - Despite the negative Earnings ESP and Zacks Rank of 4, which complicates predictions for an earnings beat, investors are advised to consider other factors before making investment decisions [12][17].

Core Viewpoint - Wall Street anticipates flat earnings for Performance Food Group (PFGC) compared to the previous year, with a focus on revenue growth impacting stock price [1][3] Earnings Expectations - The upcoming earnings report is expected to show earnings of $1.16 per share, unchanged from the year-ago quarter, with revenues projected at $16.87 billion, reflecting a 9.4% increase [3] - A positive stock movement is likely if actual results exceed these expectations, while a miss could lead to a decline [2] Estimate Revisions - The consensus EPS estimate has been revised down by 1.5% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Performance Food is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +3.58% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive reading indicates a likely earnings beat, especially when combined with a Zacks Rank of 2 [10][12] - Historical performance shows that Performance Food has beaten consensus EPS estimates only once in the last four quarters, with a recent surprise of +6.90% [13][14] Conclusion - Performance Food is positioned as a strong candidate for an earnings beat, but investors should consider additional factors before making investment decisions [17]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Quantum Computing Inc. (QUBT) despite flat revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.05 per share, reflecting a year-over-year change of +16.7%, with revenues projected at $0.1 million, unchanged from the previous year [3]. - The consensus EPS estimate has been revised 16.67% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate insights [8]. - Quantum Computing Inc. has an Earnings ESP of 0%, indicating no recent differing analyst views from the consensus estimate, and currently holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Quantum Computing Inc. was expected to post a loss of $0.06 per share and delivered exactly that, resulting in no surprise [14]. - The company has not beaten consensus EPS estimates in any of the last four quarters [15]. Conclusion - Quantum Computing Inc. does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of its earnings release [18].